Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAT-101 in Hepatocellular Carcinoma
NCT05603572Phase 2Terminated
- Sponsor
- Primocure Pharma, Inc.
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of KAT-101 in hepatocellular carcinoma (HCC) and fibrolamellar carcinoma (FLC) (3 arms), sponsored by Primocure Pharma, Inc. Primary endpoint: Recommended Phase 2 Dose at 24 months. Started Nov 2022; status: terminated.
02
Drugs
KAT-101
03
Conditions
hepatocellular carcinoma (HCC)fibrolamellar carcinoma (FLC)
Beyond the preview
Go deeper on NCT05603572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603572.